series-b
Stage
1
Investors
About
ARMGO Pharma develops novel small molecule drugs called Rycals® that target ryanodine receptor calcium ion channels to treat diseases such as RyR1-related myopathies and catecholaminergic polymorphic ventricular tachycardia (CPVT).
Explore ARMGO Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.